Literature DB >> 12111297

Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17.

Tomonori Kobayashi1, Hideo Mori, Yasuyuki Okuma, Dennis W Dickson, Natalie Cookson, Yoshio Tsuboi, Yumiko Motoi, Ryota Tanaka, Nobuo Miyashita, Midori Anno, Hirotaro Narabayashi, Yoshikuni Mizuno.   

Abstract

Association between clinical characteristics and types of the tau gene mutation has been observed in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). P301L mutation seldom causes parkinsonism as a leading symptom; instead it usually causes personality changes with aggressiveness and disinhibition. We experienced two patients of FTDP-17 from separate families (designated as patient 1 from family 1 and patient 2 from family 2). They had P301L mutation in common. However, their phenotypes were distinct from each other. Aggressive behaviors and disinhibition were the main symptoms in patient 1, whereas parkinsonism was the most prominent feature in patient 2. Their genotypes of the tau gene were different at three sites, i. e. in exon 6, in intron segment before exon 10, and in exon 13, though they do not bring amino acid change. Patient 1 had more prevalent C/C, C/C, and rare T/C respectively. Patient 2 had less prevalent T/T, A/A, and more prevalent T/T respectively. These findings suggest two things. Firstly, they do not share a common founder for P301L mutation. Secondly, either of the two less prevalent genotypes observed in patient 2 may be the factor to modify the phenotype of P301L mutation into those unusual clinical features with prominent parkinsonism. Accumulation of information as to phenotype-genotype association will settle this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111297     DOI: 10.1007/s00415-002-0687-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  8 in total

Review 1.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

2.  Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia.

Authors:  Casey Cook; Judy H Dunmore; Melissa E Murray; Kristyn Scheffel; Nawsheen Shukoor; Jimei Tong; Monica Castanedes-Casey; Virginia Phillips; Linda Rousseau; Michael S Penuliar; Aishe Kurti; Dennis W Dickson; Leonard Petrucelli; John D Fryer
Journal:  Neurobiol Aging       Date:  2013-12-26       Impact factor: 4.673

3.  Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.

Authors:  P Tacik; M Sanchez-Contreras; M DeTure; M E Murray; R Rademakers; O A Ross; Z K Wszolek; J E Parisi; D S Knopman; R C Petersen; D W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2017-03-08       Impact factor: 8.090

Review 4.  Tau alternative splicing and frontotemporal dementia.

Authors:  Amar Kar; David Kuo; Rongqiao He; Jiawei Zhou; Jane Y Wu
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

5.  Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration.

Authors:  Roberto Colombo; Daniela Tavian; Matthew C Baker; Anna M T Richardson; Julie S Snowden; David Neary; David M A Mann; Stuart M Pickering-Brown
Journal:  Neurogenetics       Date:  2009-04-14       Impact factor: 2.660

Review 6.  Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis.

Authors:  Carmen Gasca-Salas; Mario Masellis; Edwin Khoo; Binit B Shah; David Fisman; Anthony E Lang; Galit Kleiner-Fisman
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

7.  Arterial spin labeling demonstrates preserved regional cerebral blood flow in the P301L mouse model of tauopathy.

Authors:  Diana Kindler; Cinzia Maschio; Ruiqing Ni; Valerio Zerbi; Daniel Razansky; Jan Klohs
Journal:  J Cereb Blood Flow Metab       Date:  2021-11-25       Impact factor: 6.960

8.  The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.

Authors:  Ghazaleh Eskandari-Sedighi; Nathalie Daude; Hristina Gapeshina; David W Sanders; Razieh Kamali-Jamil; Jing Yang; Beipei Shi; Holger Wille; Bernardino Ghetti; Marc I Diamond; Christopher Janus; David Westaway
Journal:  Mol Neurodegener       Date:  2017-10-04       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.